CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM.
Tien JC, et al. Among authors: wang x, wang z, wang y, wang xm.
Cell Rep Med. 2024 Oct 15;5(10):101758. doi: 10.1016/j.xcrm.2024.101758. Epub 2024 Oct 4.
Cell Rep Med. 2024.
PMID: 39368479
Free PMC article.